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Opioids no better than other 
painkillers for osteoarthritis pain
A randomised, controlled 12-month trial involving 240 patients 
with chronic back pain or hip or knee osteoarthritis pain found 
that opioid drugs were no better than non-opioids at reducing pain 
that interfered with activities of daily living. The study, published in 
JAMA, also found that pain intensity was lower in the non-opioid 
group and drug-related adverse symptoms were more common in 
the opioid group.
The conclusion is that treatment with opioids was not superior 
to treatment with non-opioid drugs, and the results do not support 
starting opioid therapy for moderate to severe chronic back pain or 
hip or knee osteoarthritis pain.
Krebs EE, Gravely A, Nugent BA, et al. Effect of opioid vs nonopioid medications on pain-related function 
in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. 
JAMA 2018;319(9):872-882. https://doi.org/10.1001/jama.2018.0899
Once-off PSA screening does not 
reduce deaths from prostate cancer
Results from a trial involving >400 000 men who were invited to a 
single prostate-specific antigen (PSA) screening test for detecting 
prostate cancer showed that while more cancer was detected, there 
was no effect on prostate cancer mortality after 10 years of follow-up.
The Cluster Randomized Trial of PSA Testing for Prostate Cancer 
was conducted at 573 primary care centres in the UK and targeted 
men aged 50 - 69 years, who were followed up for 10 years. 
Among practices randomised to a single PSA screening intervention 
v. standard practice without screening, there was no significant 
difference in prostate cancer mortality, although the detection of 
low-risk prostate cancer cases increased. The findings do not support 
single PSA testing for population-based screening.
Martin RM, Donovon JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on 
prostate cancer mortality: The CAP randomized clinical trial. JAMA  2018;319(9):883-895. https://doi.
org/10.1001/jama.2018.0154
Cannabis compound may help siezures  
in drug-resistant epilepsy
A review of pooled data from 17 observational studies shows that 
seizure frequency in drug-resistant epileptic children fell by at least 
50% in just under half of the patients and stopped completely in 
nearly one in ten (8.5%) in eight of the studies. Half of the patients 
in 12 studies also reported improved quality of life. The study was 
published in the Journal of Neurology, Neurosurgery and Psychiatry.
Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: A systematic 
review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018 (epub 6 March 2018). 
https://doi.org/10.1136/jnnp-2017-317168
HRT may have a positive effect on  
heart structure
A new study published in PLoS One suggests that hormone 
replacement therapy (HRT) may have a positive effect on heart 
structure. The study was carried out using data from UK Biobank, 
a database of health questionnaire data and physical measurements, 
including cardiovascular magnetic resonance imaging. Of 1 604 
postmenopausal women without known cardiovascular disease, 
513 had used HRT for ≥3 years and 1 091 had never used it. Results 
showed lower left ventricular and higher end-diastolic volume among 
non-HRT users compared with those who used HRT. There was no 
significant difference in left ventricular mass between the two groups 
of women. The study suggests that HRT not only has no adverse 
effect on heart function but may have some positive effects on heart 
structure.
Sanghvi M, Aung N,  Cooper J, et al.  The impact of menopausal hormone therapy on cardiac structure 
and function: Insights from the UK Biobank imaging enhancement study. PLoS One 2018 (epub 8 March 
2018). https://doi.org/10.1371/journal.pone.0194015
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